<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge"/>
        <script src='echarts.min-4.8.0.js'></script>
        <script src='echarts-wordcloud.min.js'></script>
    </head>
    <body>
        <style>
            html, body, #main {
                width: 100%;
                height: 100%;
                margin: 0;
            }
        </style>
        <div id='main'></div>
        <script>
            var chart = echarts.init(document.getElementById('main'));
            var keywords = {"DATHYRCA":1,
"Follicular variant of papillary thyroid carcinoma":1,
"Incidence":1,
"NIFTP":1,
"Thyroid":16,
"Autoantibodies":1,
"Autoantigens":1,
"Breast cancer":9,
"Thyroid autoimmunity":1,
"Thyroid peroxidase":1,
"DICER1":1,
"DROSHA":1,
"Papillary thyroid carcinoma":24,
"Polymorphism":2,
"XPO5":1,
"Cancer":6,
"Intestine":1,
"Selenium":1,
"Coffee":1,
"dose–response":1,
"meta-analysis":2,
"thyroid cancer":25,
"Association prediction":1,
"Cosine similarity":1,
"Disease":1,
"Label propagation":1,
"Locality-constrained linear coding":1,
"circRNA":1,
"131I therapy":1,
"differentiated thyroid cancer":3,
"nonprivate residence":1,
"radiation safety":1,
"PI3K/AKT":1,
"TGFβ1":1,
"TMEM158":1,
"carcinogenesis":1,
"pancreatic cancer":2,
"biomarker":2,
"non-TNBC":1,
"tRFs":1,
"tumorigenesis":1,
"Endocrine toxicity":1,
"Immunotherapy":3,
"Nivolumab":1,
"Pembrolizumab":1,
"epithelial-mesenchymal transition":2,
"invasion":3,
"long noncoding RNA SLC26A4-AS1":1,
"migration":3,
"mitogen-activated protein kinase pathway":1,
"Hey2":1,
"Notch signaling pathway":1,
"microRNA-599":1,
"proliferation":5,
"cervical cancer":1,
"lncRNA PTCSC3":1,
"miR-574-5p":1,
"cytochrome P450":1,
"dioxin":1,
"endocrine disruptor":1,
"phenotyping":1,
"Differentiated thyroid carcinoma":7,
"Graves’ disease":1,
"Mortality":1,
"Recurrence":3,
"active surveillance":1,
"management":1,
"microcarcinoma":1,
"observation":1,
"outcome":1,
"Angiogenesis":1,
"Minigenes":1,
"TR3/Nur77":1,
"Tumor":1,
"shRNA":1,
"carcinoma":4,
"endocrine":1,
"head and neck":1,
"papillary":2,
"surveillance":1,
"Osteoporosis":1,
"Severe osteoporosis":1,
"American thyroid association guidelines":1,
"distant metastases":1,
"prognosis":9,
"survival":3,
"Afirma":2,
"Gene Expression Classifier":1,
"Genomic Sequencing Classifier":1,
"indeterminate cytology":1,
"thyroid nodule":10,
"Breast-axillo approach":1,
"Minimally invasive":1,
"Remote-access":1,
"Robotic":1,
"Thyroidectomy":8,
"cognitive function":1,
"depression":1,
"hypothyroidism":2,
"levothyroxine therapy":1,
"CDKN1C gene":1,
"FTIR":1,
"Gene expression":2,
"Lymph nodes metastases":1,
"Papillary thyroid cancer":5,
"Predictive molecular markers":1,
"Spectroscopy":1,
"Contrast media":1,
"Extracellular space":1,
"Multidetector computed tomography":1,
"Pancreatic ductal carcinoma":1,
"Treatment outcome":2,
"Biopsy":1,
"Cytology":4,
"Thyroid gland":2,
"Ultrasonography":6,
"Anaplastic thyroid carcinoma (ATC)":1,
"Immunohistochemistry":4,
"MRQ-50":2,
"Paired box gene 8 (PAX8)":1,
"Undifferentiated thyroid carcinoma":1,
"BRAFV600E":1,
"Hobnail":1,
"Micro papillary":1,
"Next Generation Sequencing (NGS)":1,
"TERT":2,
"CLND":1,
"endoscopic thyroidectomy":2,
"strategies":1,
"Age":1,
"Extrathyroid extension":1,
"Guidelines":1,
"Biochemical incomplete response":1,
"Dynamic risk stratification":1,
"Lung adenocarcinoma":1,
"Lymph node metastasis":4,
"Napsin A":1,
"Thyroid tumor":1,
"Hemithyroidectomy":1,
"Propensity score matching":2,
"Prophylactic central neck dissection":1,
"Thyroid lobectomy":1,
"Lymph nodes posterior to the right recurrent laryngeal nerve":1,
"Risk factors":3,
"DNA":1,
"BRAF":4,
"FNA":1,
"Histology":1,
"Suspicious for malignancy":2,
"Radioactive iodine therapy":2,
"Recombinant human thyrotropin":1,
"Response to therapy":1,
"Low-density lipoprotein":1,
"indocyanine green":1,
"photothermal therapy":1,
"silica nanoparticles":1,
"BRAF mutation":1,
"fine-needle aspiration cytology":1,
"personalized medicine":1,
"programmed death-ligand 1 (PD-L1)":1,
"Lateral lymph node metastasis":1,
"Recurrence-free survival":1,
"Skip metastasis":1,
"Calcitonin-negative medullary thyroid carcinoma":1,
"Medullary thyroid carcinoma":6,
"Neuroendocrine":1,
"atypia of undetermined significance":2,
"fine-needle aspiration":2,
"spherule":1,
"COL5A1":1,
"circRNA ACAP2":1,
"miR-29a-3p":1,
"miR-29b-3p":1,
"RECIST":1,
"doubling time":1,
"lung metastases":1,
"Cell proliferation":2,
"DTC":1,
"Levothyroxine":1,
"SREBP1":1,
"FT-IR":1,
"Multivariate analysis":1,
"Papillary carcinoma":3,
"Psammoma bodies":1,
"Fine-needle aspiration (FNA)":2,
"Monoclonal PAX8":1,
"PAX8 antibody":1,
"Chicken chorioallantoic membrane":1,
"Combination chemotherapy":1,
"Fingolimod":1,
"Folate receptor":1,
"Mesoporous silica nanoparticles":1,
"Methotrexate":1,
"Surface functionalization":1,
"Targeted drug delivery":1,
"BACH2":1,
"Exosomes":1,
"Kras":1,
"Necroptosis":1,
"miR-146/miR-210":1,
"Cell phone":1,
"Genetic susceptible":1,
"Genetic-environment interaction":1,
"Radiofrequency radiation":1,
"C cell hyperplasia":1,
"C cells":1,
"Calcitonin":1,
"HRD1":1,
"SIRT2":1,
"histone deacetylase":1,
"lung cancer":1,
"ubiquitination":1,
"4D-CT":1,
"computed tomography":1,
"dual-energy CT":1,
"parathyroid adenoma":1,
"quantitative information":1,
"anaplastic thyroid carcinoma":2,
"mimic":1,
"plasmacytoma":1,
"malignancy":2,
"pancreas":1,
"synchronous tumour":1,
"international experience":1,
"natural orifice transluminal endoscopic surgery":1,
"remote access surgery":1,
"transoral thyroid surgery":1,
"Cervical embryonal rhabdomyosarcoma":1,
"DICER1-related multinodular goiter":1,
"Ovarian sex-cord stromal tumors":1,
"Pleuropulmonary blastoma":1,
"Sertoli-Leydig cell tumors of the ovary":1,
"Long non-coding RNA":1,
"Tumor suppressor":1,
"guideline":1,
"nodule":2,
"risk":1,
"stratification":1,
"ultrasound":2,
"Genetics":1,
"TIR3B":1,
"Agricultural workers":1,
"DNA damage":1,
"Farmworkers":1,
"Pesticide exposure":1,
"Synthetic pesticides":1,
"cancer survivorship":1,
"cardiovascular diseases":1,
"cause of death":1,
"neoplasms":2,
"noncancer mortality":1,
"suicide":1,
"health care":1,
"high-volume hospitals":1,
"quality indicators":1,
"quality of care":1,
"Blood analysis":1,
"Screening":1,
"Silver nanoparticles":1,
"Surface-enhanced Raman spectroscopy":1,
"Surgery assessment":1,
"Diffusion magnetic resonance imaging":1,
"Reproducibility of results":1,
"Clinical":1,
"Grade":1,
"Lymphoma":2,
"Primary":1,
"1,25-Dihydroxy vitamin D3 [1,25-(OH)(2)D(3)]":1,
"Apoptosis":3,
"Ras-MEK-ERK pathway":1,
"Right paraesophageal lymph node":1,
"EMT":1,
"PTC":2,
"SCARA5":1,
"HK2":1,
"Resibufogenin":1,
"Warburg effect":1,
"miR-143-3p":1,
"Molecular genetics":1,
"Remission":1,
"APC":1,
"cribriform–morular variant":1,
"familial adenomatous polyposis":1,
"whole-genome sequencing":1,
"Candidate genes":1,
"Hereditary papillary thyroid carcinoma":1,
"Inherited predisposition":1,
"Whole exome sequencing":1,
"PTEN":1,
"hepatocellular carcinoma":2,
"miR-552":1,
"sorafenib":1,
"tumor-initiating cells":1,
"TLR4":1,
"ceRNAs":1,
"circFNDC3B":1,
"exosome":2,
"miR-1178":1,
"FSCN1":1,
"Methylation":1,
"Promoter":1,
"cytokine":1,
"immune-related adverse events":1,
"thyroglobulin":1,
"thyroid dysfunction":1,
"Computer-aided diagnosis":1,
"Radiofrequency ablation":2,
"Safety":1,
"lenvatinib":1,
"neutrophil-to-lymphocyte ratio":1,
"prognostic factors":1,
"Thyrogen":1,
"Thyroxine":1,
"HPV (human papilloma virus)":1,
"Head and neck squamous cell carcinoma":1,
"Lymphadenopathy":1,
"Metastasis of unknown primary":1,
"Disease-specific survival":1,
"SEER database":2,
"elderly people":1,
"risk factor":1,
"SEER Program":1,
"da Vinci SP robotic system":1,
"robotic surgery":1,
"transaxillary":1,
"Age at diagnosis":1,
"Tumor size":1,
"GWAS":1,
"polygenic risk score":1,
"risk prediction":1,
"Hashimoto thyroiditis":1,
"autoantibody":1,
"histopathology":1,
"Gallium":1,
"Lutetium":1,
"PET/CT":2,
"Prostate-specific membrane antigen":1,
"Radioactive iodine-refractory differentiated thyroid carcinoma":1,
"Theranostic":1,
"Asphyxia":1,
"Cultured cell":1,
"Ischemia/hypoxia":1,
"Thyroid hormone":1,
"Thyroid-stimulating hormone":1,
"Lupus erythematosus, systemic":1,
"VE1":1,
"diagnostic performance":1,
"TP53":1,
"immune/chemotherapy":1,
"lung squamous cell carcinoma":1,
"signature":1,
"Carcinoma larynx":1,
"Contrast enhanced CT":1,
"Total laryngectomy":1,
"Disease gene prediction":1,
"Ensemble learning":1,
"Network centrality":1,
"Protein-protein interaction network":1,
"Sample-based networks":1,
"Fine-needle aspiration biopsy":2,
"Thyroid nodules":1,
"WGCNA":1,
"Biomarkers":1,
"Inflammatory markers":1,
"estrogen receptor alpha, NR2F2, cistrome, active histone modifications, chromatin interactions, breast cancer, luminal A subtype":1,
"STAT3":1,
"autophagy":1,
"cisplatin":1,
"sanguinarine":1,
"CVID":1,
"common variable immunodeficiency":1,
"lymphoproliferation":1,
"lymphoproliferative disease":1,
"lymphoproliferative disorder":1,
"Polymerase chain reaction":1,
"Thyroid neoplasm":1,
"131I-SPECT/CT":1,
"131I-whole body scan (WBS)":1,
"Differentiated thyroid carcinoma (DTC)":3,
"Long-term follow-up":1,
"Neck lymph node metastases":1,
"Papillary carcinoma of thyroid":1,
"Total thyroidectomy":1,
"Voice Handicap Index":1,
"Voice change after thyroidectomy":1,
"Weight and volume of thyroid gland":1,
"Carcinoma thyroid":1,
"Laryngeal resection":1,
"Tracheal resection":1,
"Genome":1,
"High-throughput nucleotide sequencing":1,
"Thyroid carcinoma, anaplastic":1,
"Thyroid neoplasms":4,
"Transcriptome":1,
"Papillary thyroid microcarcinoma":1,
"Quality of life":1,
"Radioactive iodine":1,
"Richter’s syndrome":1,
"chronic lymphocytic leukemia":1,
"liver":1,
"Acellular dermis":1,
"Breast reconstruction":1,
"Breast-conserving surgery":1,
"Collision carcinoma":1,
"Laryngeal carcinoma":1,
"Neuroendocrine carcinoma":1,
"Squamous cell carcinoma":2,
"Breast metastasis":1,
"Extra-mammary":1,
"Intraductal lesion":1,
"Male breast cancer":1,
"Ureteral cancer":1,
"epidemiology":1,
"neoplasm":1,
"occupational exposure":1,
"radiation":1,
"OTUD6B-AS1":1,
"lncRNA":1,
"miR-183-5p":1,
"miR-21":1,
"microRNA":2,
"thyroid carcinoma":3,
"bethesda":1,
"Oral metastatic carcinoma":1,
"Oral soft tissue":1,
"cellularity":1,
"liquid-based cytology":1,
"molecular testing":1,
"next-generation sequencing (NGS)":1,
"nucleic acid quality":1,
"nucleic acid yield":1,
"storage time":1,
"Glucocorticoids":1,
"Hypocalcemia":1,
"Hypoparathyroidism":1,
"Neck dissection":1,
"Da Vinci robotic surgical system":1,
"Retroauricular approach":1,
"Accuracy":1,
"Bethesda system":1,
"Fine needle aspiration":1,
"Risk of malignancy":1,
"Laryngeal neoplasms":1,
"SEER":1,
"gender":1,
"BRAF V600E":1,
"PAX-8":1,
"TTF-1":1,
"dedifferentiated squamous cell carcinoma":1,
"tall cell variant":1,
"CVVHD":1,
"continuous venovenous hemodialysis":1,
"giant parathyroid adenoma":1,
"hypercalcemia":1,
"Nasopharyngeal carcinoma":1,
"Radiation therapy":1,
"Insular carcinoma":1,
"Poorly differentiated thyroid carcinoma":1,
"RAS":1,
"Turin proposal":1,
"thyroid imaging reporting and data systems":1,
"ultrasound examination":1,
"Chemo-resistance":1,
"Inflammation":2,
"diabetes mellitus":1,
"mendelian randomization":1,
"molecular epidemiology":1,
"obesity":1,
"type 2":1,
"diagnostic accuracy":1,
"lateral neck metastasis":1,
"Thyroglossal duct neoplasms":1,
"head and neck cancer":1,
"thyroglossal duct remnant":1,
"ROCK1":1,
"malignant proliferation and diffusion":1,
"miR-135a":1,
"non-small cell lung carcinoma":1,
"vitamin D":1,
"vitamin D receptor":1,
"RNA targeted sequencing":1,
"fusion genes":1,
"pediatric":1,
"rearrangements":1,
"Chemotherapy":2,
"Metformin":1,
"Ovarian toxicity":1,
"Liver metastasis":1,
"Liver surgery":1,
"K-TIRADS":1,
"isthmic":1,
"high risk":1,
"predictive factors":1,
"Cervical lymph nodes":1,
"Cystic lesion":1,
"Metastasis":2,
"Lateral neck dissection":1,
"Scarless endoscopic thyroidectomy":1,
"NF1 gene":1,
"RET proto-oncogene":1,
"children":2,
"vandetanib":1,
"Cell Biology":1,
"Molecular Biology":1,
"COVID-19":1,
"adrenal cancer":1,
"pathways":1,
"prostate cancer":1,
"standard operating procedures":1,
"targeted therapies":1,
"Adipokines":1,
"IL-6":1,
"Leptin":1,
"TNF-α":1,
"central lymph node metastasis":1,
"elderly patients":1,
"micro-carcinoma":1,
"Anaplastic":1,
"PD-L1":1,
"Squamous":1,
"Betulinic acid":1,
"Cell proliferation and migration":1,
"Gastric cancer":1,
"NF-κB":1,
"VASP":1,
"Positive tumor margin":1,
"Relapse-free survival":1,
"Surveillance, Epidemiology, and End Results (SEER)":1,
"synergic effect":1,
"Kelch-like ECH-associated protein 1 (Keap1)":1,
"Nfe2l2":1,
"RNA-Seq":1,
"fibrosis":1,
"immune response":1,
"iodine":1,
"oxidative stress":1,
"TC":1,
"TF-Ab":1,
"TF-Ag":1,
"Thomsen–Friedenreich antibody":1,
"Thomsen–Friedenreich antigen":1,
"mAb A78-G/A7":1,
"Non-coding RNA":1,
"Receptors":1,
"Immune infiltration":1,
"Papillary thyroid carcinoma (PTC)":1,
"Tumor mutation burden (TMB)":1,
"FAM172A":1,
"follicular thyroid adenoma":1,
"follicular thyroid carcinoma":1,
"juvenile":1,
"Notch signaling":1,
"cell growth":1,
"invasion and migration":1,
"semaphorin 6B":1,
"Expression profile":1,
"Parathyroid carcinoma":1,
"ANGPTL2":1,
"CSN5":1,
"PGT-M":1,
"assisted reproductive technology":1,
"multiple endocrine neopasia type 2":1,
"rearranged during transfection (RET)":1,
"glycolysis":1,
"β-elemene":1,
"PET‐CT":1,
"RCC":1,
"fine‐needle biopsy":1,
"ACC, adrenocortical carcinoma":1,
"BLCA, bladder urothelial carcinoma":1,
"BRCA, breast invasive carcinoma":1,
"CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma":1,
"CHOL, cholangiocarcinoma":1,
"COAD, colon adenocarcinoma":1,
"Cancer therapy":1,
"DLBC, lymphoid neoplasm diffuse large B-cell lymphoma":1,
"ESCA, esophageal carcinoma":1,
"GBM, glioblastoma multiforme":1,
"HNSC, head and neck squamous cell carcinoma":1,
"KICH, kidney chromophobe":1,
"KIRC, kidney renal clear cell carcinoma":1,
"KIRP, kidney renal papillary cell carcinoma":1,
"LAML, acute myeloid leukemia":1,
"LGG, brain lower grade glioma":1,
"LIHC, liver hepatocellular carcinoma":1,
"LUAD, lung adenocarcinoma":1,
"LUSC, lung squamous cell carcinoma":1,
"MESO, mesothelioma":1,
"OV, ovarian serous cystadenocarcinoma":1,
"PAAD, pancreatic adenocarcinoma":1,
"PCPG, pheochromocytoma and paraganglioma":1,
"PRAD, prostate adenocarcinoma":1,
"Pan-cancer analysis":1,
"READ, rectum adenocarcinoma":1,
"RNA interaction":1,
"SARC, sarcoma":1,
"SKCM, skin cutaneous melanoma":1,
"STAD, stomach adenocarcinoma":1,
"Synthetic lethality":1,
"TGCT, testicular germ cell tumors":1,
"THCA, thyroid carcinoma":1,
"THYM, thymoma":1,
"TSG, tumor suppressor gene":1,
"UCEC, uterine corpus endometrial carcinoma":1,
"UCS, uterine carcinosarcoma":1,
"UVM, uveal melanoma":1,
"Cystadenocarcinoma":1,
"Cystadenoma":1,
"Mesenteric cyst":1,
"Mesentery":1,
"Mesocolon":1,
"PET":1,
"parapharyngeal space":1,
"retropharyngeal space":1,
"well-differentiated thyroid cancer":1            };
            var data = [];
            for (var name in keywords) {
                data.push({
                    name: name,
                    value: Math.sqrt(keywords[name])
                })
            }
            var maskImage = new Image();
            var option = {
	             title: {
                text: '2020年3月论文keyword词云'
            },
                series: [ {
                    type: 'wordCloud',
                    sizeRange: [15, 100],
                    rotationRange: [-90, 90],
                    rotationStep: 45,
                    gridSize: 2,
                    shape: 'pentagon',
                    maskImage: maskImage,
                    drawOutOfBound: false,
                    textStyle: {
                        normal: {
                            color: function () {
                                return 'rgb(' + [
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160),
                                    Math.round(Math.random() * 160)
                                ].join(',') + ')';
                            }
                        },
                        emphasis: {
                            color: 'red'
                        }
                    },
                    data: data.sort(function (a, b) {
                        return b.value  - a.value;
                    })
                } ]
            };
            maskImage.onload = function () {
                option.series[0].maskImage
                chart.setOption(option);
            }
            maskImage.src = 'data:image/png;base64,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';
            window.onresize = function () {
                chart.resize();
            }
        </script>
    </body>
</html>
